Clinical implications of growth hormone-secreting tumor subtypes

Endocrine

Volumn 42, Issue 1, 2012, Pages 18-28

  Kiseljak Vassiliades, Katja ^a,b   Shafi, Shibana ^a   Kerr, Janice M ^a   Phang, Tzu L ^c   Kleinschmidt DeMasters, B K ^a   Wierman, Margaret E ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Acromegaly; Densely granulated adenoma; Growth hormone tumor; Pituitary adenoma; Sparsely granulated adenoma

Indexed keywords

CYTOKERATIN; GROWTH HORMONE RECEPTOR; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR;

AGE DISTRIBUTION; CLINICAL FEATURE; DENSELY GRANULATED ADENOMA; DISEASE ACTIVITY; ELECTRON MICROSCOPY; GENE MUTATION; GROWTH HORMONE RELEASE; GROWTH HORMONE SECRETING ADENOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR PATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SINGLE DRUG DOSE; SPARSELY GRANULATED ADENOMA; TRANSSPHENOIDAL SURGERY; TREATMENT RESPONSE; TUMOR CLASSIFICATION; TUMOR RECURRENCE; TUMOR VOLUME;

EID: 84865036732     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9660-9     Document Type: Review

References (62)

1. S.L. Asa, S. Ezzat, The pathogenesis of pituitary tumors. Annu. Rev. Pathol. 4, 97-126 (2009). doi:10.1146/annurev.pathol. 4.110807.092259
2. S. Melmed, Acromegaly pathogenesis and treatment. J. Clin. Invest. 119(11), 3189-3202 (2009). doi:10.1172/JCI3937539375
3. I. Shimon, Z.R. Cohen, Z. Ram, M. Hadani, Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery 48(6), 1239-1243 (2001). Discussion 1244-1235
4. A. Giustina, P. Chanson, M.D. Bronstein, A. Klibanski, S. Lamberts, F.F. Casanueva, P. Trainer, E. Ghigo, K. Ho, S. Melmed, A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95(7), 3141-3148 (2010). doi:10.1210/ jc.2009-2670
5. S. Melmed, A. Colao, A. Barkan, M. Molitch, A.B. Grossman, D. Kleinberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, M.L. Vance, K. Ho, A. Giustina, Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94(5), 1509-1517 (2009). doi:10.1210/jc.2008-2421
6. I. Donangelo, S. Melmed, Treatment of acromegaly: future. Endocrine 28(1), 123-128 (2005). doi:10.1385/ENDO:28:1:123
7. A. Stevenaert, A. Beckers, Presurgical Octreotide: treatment in acromegaly. Metabolism 45(8 Suppl 1), 72-74 (1996)
8. D.R. Clemmons, K. Chihara, P.U. Freda, K.K. Ho, A. Klibanski, S. Melmed, S.M. Shalet, C.J. Strasburger, P.J. Trainer, M.O. Thorner, Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J. Clin. Endocrinol. Metab. 88(10), 4759-4767 (2003)
9. J.D. Carmichael, V.S. Bonert, J.M. Mirocha, S. Melmed, The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J. Clin. Endocrinol. Metab. 94(2), 523-527 (2009). doi: 10.1210/jc.2008-1371
10. A. Giustina, T. Porcelli, Pituitary gland: medical therapy for acromegaly: can we predict response? Nat. Rev. Endocrinol. 5(8), 425-427 (2009). doi:10.1038/nrendo.2009.146
11. P.U. Freda, Somatostatin analogs in acromegaly. J. Clin. Endocrinol. Metab. 87(7), 3013-3018 (2002)
12. P.J. Trainer, S. Ezzat, G.A. D'Souza, G. Layton, C.J. Strasburger, A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and longacting octreotide in patients with acromegaly. Clin. Endocrinol. 71(4), 549-557 (2009). doi:10.1111/j.1365-2265. 2009.03620.x
13. P. Lundin, B. Eden Engstrom, F.A. Karlsson, P. Burman, Longterm octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR. AJNR Am. J. Neuroradiol. 18(4), 765-772 (1997)
14. C. Salaun, L. Foubert, M. Vialatou, M. Kujas, G. Turpin, Prognostic factors in the surgical management of acromegaly. Ann. Med. Interne 150(3), 195-198 (1999)
15. P. Nomikos, M. Buchfelder, R. Fahlbusch, The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur. J. Endocrinol. 152(3), 379-387 (2005). doi:10.1530/eje.1.01863
16. A. Abosch, J.B. Tyrrell, K.R. Lamborn, L.T. Hannegan, C.B. Applebury, C.B. Wilson, Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J. Clin. Endocrinol. Metab. 83(10), 3411-3418 (1998)
17. Roelfsema, F., Biermasz, N.R., Pereira, A.M.: Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary (2011). doi:10.1007/s11102-011-0347-7
18. A. Fusco, M.C. Zatelli, A. Bianchi, V. Cimino, L. Tilaro, F. Veltri, F. Angelini, L. Lauriola, V. Vellone, F. Doglietto, M.R. Ambrosio, G. Maira, A. Giustina, E.C. degli Uberti, A. Pontecorvi, L. De Marinis, Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas. J. Clin. Endocrinol. Metab. 93(7), 2746-2750 (2008). doi: 10.1210/jc.2008-0126
19. C.H. Botelho, A.V. Magalhaes, P.A. Mello, F.C. Schmitt, L.A. Casulari, Expression of p53, Ki-67 and c-erb B2 in growth hormone- and/or prolactin-secreting pituitary adenomas. Arq. Neuropsiquiatr. 64(1), 60-66 (2006). doi:/S0004-282X200600010 0013
20. K. Yonezawa, N. Tamaki, T. Kokunai, Clinical features and growth fractions of pituitary adenomas. Surg. Neurol. 48(5), 494-500 (1997)
21. S.S. Zuhur, C. Tanik, O. Karaman, S. Velet, E. Cil, F.Y. Ozturk, H. Ozkayalar, A.M. Musluman, Y. Altuntas, MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern. Endocrine 40(2), 222-227 (2011). doi: 10.1007/s12020-011-9485-y
22. G. Kontogeorgos, Classification and pathology of pituitary tumors. Endocrine 28(1), 27-35 (2005). doi:10.1385/ENDO: 28:1:027
23. S. Bhayana, G.L. Booth, S.L. Asa, K. Kovacs, S. Ezzat, The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J. Clin. Endocrinol. Metab. 90(11), 6290-6295 (2005). doi:10.1210/jc.2005-0998
24. Asa, S.L.: Tumors of the pituitary gland. Atlas of Tumor Pathology, vol. Third Series; Fasicle 22. Armed Forces Institute of Pathology, Washington, DC (1998)
25. M.B. Lopes, Growth hormone-secreting adenomas: pathology and cell biology. Neurosurg. Focus 29(4), E2 (2010). doi: 10.3171/2010.7.FOCUS10169
26. K. Kovacs, E. Horvath, B. Corenblum, A.M. Sirek, G. Penz, C. Ezrin, Pituitary chromophobe adenomas consisting of prolactin cells: a histologic, immunocytological and electron microscopic study. Virchows Arch. A Pathol. Anat. Histol. 366(2), 113-123 (1975)
27. E. Horvath, K. Kovacs, Ultrastructural classification of pituitary adenomas. Can. J. Neurol. Sci. 3(1), 9-21 (1976)
28. T. Sano, T. Ohshima, S. Yamada, Expression of glycoprotein hormones and intracytoplasmic distribution of cytokeratin in growth hormone-producing pituitary adenomas. Pathol. Res. Pract. 187(5), 530-533 (1991)
29. V. Karantza, Keratins in health and cancer: more than mere epithelial cell markers. Oncogene 30(2), 127-138 (2011). doi: 10.1038/onc.2010.456
30. H. Bando, T. Sano, T. Ohshima, C.Y. Zhang, R. Yamasaki, K. Matsumoto, S. Saito, Differences in pathological findings and growth hormone responses in patients with growth hormoneproducing pituitary adenoma. Endocrinol. Jpn. 39(4), 355-363 (1992)
31. A. Obari, T. Sano, K. Ohyama, E. Kudo, Z.R. Qian, A. Yoneda, N. Rayhan, M. Mustafizur Rahman, S. Yamada, Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr. Pathol. 19(2), 82-91 (2008). doi:10.1007/s12022-008-9029-z
32. P.R. Mazal, T. Czech, R. Sedivy, M. Aichholzer, J. Wanschitz, N. Klupp, H. Budka, Prognostic relevance of intracytoplasmic cytokeratin pattern, hormone expression profile, and cell proliferation in pituitary adenomas of akromegalic patients. Clin. Neuropathol. 20(4), 163-171 (2001)
33. S. Yamada, T. Aiba, T. Sano, K. Kovacs, Y. Shishiba, S. Sawano, K. Takada, Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology. Neurosurgery 33(1), 20-27 (1993)
34. Y. Bakhtiar, H. Hirano, K. Arita, S. Yunoue, S. Fujio, A. Tominaga, T. Sakoguchi, K. Sugiyama, K. Kurisu, J. Yasufuku-Takano, K. Takano, Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae. Eur. J. Endocrinol. 163(4), 531-539 (2010). doi:10.1530/EJE-10-0586
35. J. Kreutzer, M.L. Vance, M.B. Lopes, E.R. Laws Jr, Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J. Clin. Endocrinol. Metab. 86(9), 4072-4077 (2001)
36. I.A. Felix, E. Horvath, K. Kovacs, H.S. Smyth, D.W. Killinger, J. Vale, Mammosomatotroph adenoma of the pituitary associated with gigantism and hyperprolactinemia. A morphological study including immunoelectron microscopy. Acta Neuropathol. 71(1-2), 76-82 (1986)
37. S.L. Fougner, O. Casar-Borota, A. Heck, J.P. Berg, J. Bollerslev, Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin. Endocrinol. 76(1), 96-102 (2012). doi:10.1111/j.1365-2265.2011.04163.x
38. J. Hardy, Transsphenoidial microsurgical treatment of pituitary tumours, in Recent Advances in the Diagnosis and Treatment of Pituitary Tumours, ed. by L. Linfoot (Raven Press, New York, 1979), pp. 375-387
39. E. Knosp, E. Steiner, K. Kitz, C. Matula, Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33(4), 610-617 (1993). Discussion: 617-618
40. A. Hagiwara, Y. Inoue, K. Wakasa, T. Haba, T. Tashiro, T. Miyamoto, Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology 228(2), 533-538 (2003). doi:10.1148/radiol.22820206952282020695
41. A. Heck, G. Ringstad, S.L. Fougner, O. Casar-Borota, T. Nome, J. Ramm-Pettersen, J. Bollerslev, Intensity of pituitary adenoma on T2 weighted MRI predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin. Endocrinol. (2011). doi: 10.1111/j.1365-2265.2011.04286.x
42. S. Ahmed, M. Elsheikh, I.M. Stratton, R.C. Page, C.B. Adams, J.A. Wass, Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin. Endocrinol. 50(5), 561-567 (1999)
43. C. Beauregard, U. Truong, J. Hardy, O. Serri, Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin. Endocrinol. 58(1), 86-91 (2003)
44. M. Arosio, M.A. Giovanelli, E. Riva, C. Nava, B. Ambrosi, G. Faglia, Clinical use of pre- and postsurgical evaluation of abnormal GH responses in acromegaly. J. Neurosurg. 59(3), 402-408 (1983). doi:10.3171/jns.1983.59.3.0402
45. S.J. Brockmeier, M. Buchfelder, R. Fahlbusch, TRH/GnRH test in acromegaly. Long-term follow-up experience with successfully treated patients. Horm. Metab. Res. 25(5), 275-277 (1993). doi: 10.1055/s-2007-1002096
46. N.R. Biermasz, J.W. Smit, H. van Dulken, F. Roelfsema, Postoperative persistent thyrotrophin releasing hormone-induced growth hormone release predicts recurrence in patients with acromegaly. Clin. Endocrinol. 56(3), 313-319 (2002)
47. S. Valdemarsson, S. Ljunggren, M. Bramnert, O. Norrhamn, C.H. Nordstrom, Early postoperative growth hormone levels: high predictive value for long-term outcome after surgery for acromegaly. J. Intern. Med. 247(6), 640-650 (2000)
48. C.L. Ronchi, V. Varca, C. Giavoli, P. Epaminonda, P. Beck- Peccoz, A. Spada, M. Arosio, Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria. J. Clin. Endocrinol. Metab. 90(3), 1377-1382 (2005). doi:10.1210/jc.2004-1974
49. L. De Marinis, A. Mancini, A. Bianchi, R. Gentilella, D. Valle, A. Giampietro, P. Zuppi, C. Anile, G. Maira, A. Giustina, Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients. Metab. Clin. Exp. 51(5), 616-621 (2002)
50. B. Xu, T. Sano, K. Yoshimoto, S. Yamada, Downregulation of E-cadherin and its undercoat proteins in pituitary growth hormone cell adenomas with prominent fibrous bodies. Endocr. Pathol. 13(4), 341-351 (2002). doi:EP:13:4:341
51. T. Sano, Q.Z. Rong, N. Kagawa, S. Yamada, Down-regulation of E-cadherin and catenins in human pituitary growth hormoneproducing adenomas. Front. Horm. Res. 32, 127-132 (2004)
52. H. McNeill, M. Ozawa, R. Kemler, W.J. Nelson, Novel function of the cell adhesion molecule uvomorulin as an inducer of cell surface polarity. Cell 62(2), 309-316 (1990). doi:0092-8674(90) 90368-O
53. T. Brabletz, F. Hlubek, S. Spaderna, O. Schmalhofer, E. Hiendlmeyer, A. Jung, T. Kirchner, Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal- epithelial transition, stem cells and beta-catenin. Cells Tissues Organs 179(1-2), 56-65 (2005). doi:10.1159/000084509
54. M.J. Wheelock, K.R. Johnson, Cadherins as modulators of cellular phenotype. Annu. Rev. Cell Dev. Biol. 19, 207-235 (2003). doi:10.1146/annurev. cellbio.19.011102.111135
55. L. Vallar, A. Spada, G. Giannattasio, Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 330(6148), 566-568 (1987). doi:10.1038/330566a0
56. C.A. Landis, S.B. Masters, A. Spada, A.M. Pace, H.R. Bourne, L. Vallar, GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 340(6236), 692-696 (1989). doi:10.1038/340692a0
57. A. Spada, M. Arosio, D. Bochicchio, N. Bazzoni, L. Vallar, M. Bassetti, G. Faglia, Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J. Clin. Endocrinol. Metab. 71(6), 1421-1426 (1990)
58. F.H. Burton, K.W. Hasel, F.E. Bloom, J.G. Sutcliffe, Pituitary hyperplasia and gigantism in mice caused by a cholera toxin transgene. Nature 350(6313), 74-77 (1991). doi:10.1038/ 350074a0
59. S.L. Asa, R. Digiovanni, J. Jiang, M.L. Ward, K. Loesch, S. Yamada, T. Sano, K. Yoshimoto, S.J. Frank, S. Ezzat, A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer Res. 67(15), 7505-7511 (2007). doi:10.1158/0008-5472.CAN-07-0219
60. B. Kola, M. Korbonits, S. Diaz-Cano, G. Kaltsas, D.G. Morris, S. Jordan, L. Metherell, M. Powell, S. Czirjak, G. Arnaldi, S. Bustin, M. Boscaro, F. Mantero, A.B. Grossman, Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor. Clin. Endocrinol. 59(3), 328-338 (2003)
61. S.L. Asa, K.T. Coschigano, L. Bellush, J.J. Kopchick, S. Ezzat, Evidence for growth hormone (GH) autoregulation in pituitary somatotrophs in GH antagonist-transgenic mice and GH receptordeficient mice. Am. J. Pathol. 156(3), 1009-1015 (2000). doi: 10.1016/S0002-9440(10)64968-1
62. S. Ezzat, G. Kontogeorgos, D.A. Redelmeier, E. Horvath, A.G. Harris, K. Kovacs, In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. Eur. J. Endocrinol. 133(6), 686-690 (1995)